Pharmacy & Regulation
Compounded Peptides, Explained: 503A, 503B, FDA and How to Judge Pharmacy Quality
A compounded medication is not an FDA-approved drug. It is a legal, distinct regulatory pathway with its own rules — and understanding those rules is the difference between safe, physician-directed peptide therapy and a research-chemical purchase dressed up in medical language. This page covers what 503A and 503B mean, how the do-not-compound list works, what actually happens inside a compounding pharmacy, and the specific quality signals to look for before accepting a compounded peptide prescription.
What 503A means, in plain terms
Section 503A of the Federal Food, Drug, and Cosmetic Act is the part of federal drug law that allows a licensed pharmacy to compound (prepare) medications for an individual patient based on a physician's prescription. The pharmacy can use bulk drug substances that appear on the FDA's positive list, that are components of FDA-approved drugs, or that have an applicable USP monograph. They cannot use substances that the FDA has placed on the "do not compound" list pending review.
503A compounding is a decades-old, well-established practice. It is how bioidentical hormone preparations are made when a patient needs a dose or delivery route that is not commercially available. It is how liquid formulations are prepared for patients who cannot swallow tablets. It is how allergy-free preparations are made for patients who react to inactive ingredients in commercial drugs. Peptide compounding is a newer, more visible category of the same underlying pathway.
What 503B is and how it differs
Section 503B, added to the Federal Food, Drug, and Cosmetic Act by the Drug Quality and Security Act of 2013, created a new class of "outsourcing facilities." A 503B facility is FDA-registered, inspected under cGMP, and can produce larger batches of medications for office-use dispensing without a patient-specific prescription in advance. In practice, 503B facilities operate closer to a small-batch drug manufacturer than a traditional pharmacy, and their quality controls are correspondingly more stringent.
For patient-specific peptide prescriptions, 503A is the standard pathway. For clinic-administered injectables provided at scale, 503B is common. Both are legitimate; both require the same underlying regulatory compliance for the substances being compounded.
What the do-not-compound list is, and why it matters
When the FDA receives a nomination to add a substance to the 503A bulk drug substances list, the agency reviews the substance for safety, effectiveness, historical use, and characterization. While under review, the FDA can place it in Category 2 — meaning it cannot be compounded until the review is complete. BPC-157, CJC-1295, ipamorelin, thymosin alpha-1, and several other peptides were placed in Category 2 in 2023–2024. The July 2026 PCAC meeting is the next review milestone at which several of these substances will be re-evaluated.
A pharmacy that continues to compound a Category 2 substance is operating outside current FDA guidance. Patients receiving such a prescription face two related risks: the regulatory exposure of the pharmacy itself (which can trigger cease-and-desist actions and product withdrawal), and — more directly — the quality risk of preparations made outside the standards the FDA is currently evaluating.
Compounded ≠ FDA-approved. This is not a technicality.
FDA approval is a finished-product designation: a specific manufacturer submits pre-clinical and clinical safety and efficacy data through a New Drug Application (NDA), the FDA reviews the data, and — if approved — the drug is licensed with a specific label, indication, dose, and manufacturing process. Ozempic and Wegovy are examples for semaglutide; Mounjaro and Zepbound for tirzepatide. A compounded medication, by contrast, is prepared from raw active pharmaceutical ingredients for a specific patient. It is legal and widely used, but it is not FDA-approved at the drug-product level.
Any marketing that describes a compounded medication as "FDA-approved" is a regulatory misstatement. The API may come from a source that manufactures FDA-approved products, and the pharmacy may be state-licensed, but the finished compounded preparation is not FDA-approved and cannot be described that way.
What to look for in a compounding pharmacy
- Licensure in the state where the patient resides. Cross-state compounding requires the pharmacy to be licensed in the receiving state. A pharmacy that fills prescriptions across state lines without appropriate licensure is out of compliance.
- Clean state board of pharmacy inspection record. Inspection reports are public. Repeat citations for sterility failures, labeling issues, or beyond-use-date violations are meaningful.
- USP <797> compliance for sterile preparations. Any injectable — which includes most peptides — must be prepared in a USP <797> compliant clean environment with documented sterility testing.
- USP <800> compliance where hazardous drug handling is relevant.
- Transparent API sourcing. The active pharmaceutical ingredient should come from an FDA-registered supplier. The pharmacy should be able to name the API supplier and produce documentation.
- Certificate of analysis (COA) available on request. For every batch, the pharmacy should have a COA covering identity, potency, and sterility. If they will not provide one, ask why.
- Beyond-use date (BUD) that reflects stability data. A conservative BUD is a good sign; a suspiciously long one is not.
- PCAB accreditation is a positive signal. Not required, but Pharmacy Compounding Accreditation Board accreditation indicates the pharmacy has been externally audited against national compounding standards.
Red flags that should end the conversation
- The prescriber offers a peptide without labs or a documented clinical evaluation.
- The pharmacy ships across state lines without appropriate licensure.
- Marketing claims a compounded product is "FDA-approved."
- The substance being prescribed is currently on the do-not-compound list.
- No certificate of analysis is available and the pharmacy declines to explain sourcing.
- The prescriber is not licensed in your state.
Why this matters for peptide therapy specifically
Peptides are proteins. They fold, degrade, aggregate, and lose potency in ways that small-molecule drugs do not. Sterility, cold-chain handling, and batch consistency matter more, not less, for peptide preparations. A compounding pharmacy that cuts corners on any of these dimensions is not just delivering a lower-quality medication — it is potentially delivering a preparation that has degraded to a different chemical entity than what was on the label. This is the single largest quality risk in the compounded peptide space today, and it is why pharmacy selection is not a downstream operational decision. It is a clinical one.
How kindr Health handles this
We work with 503A partner pharmacies that meet the criteria above. We do not prescribe medications that are on the FDA do-not-compound list. Every peptide prescription is preceded by a physician evaluation, appropriate labs, and — where clinically relevant — an IGF-1 baseline for growth-hormone-axis peptides. We do not sell peptides direct-to-consumer and we do not ship internationally.
Learn more about our Longevity service →
Is BPC-157 legal in the U.S.? →
FDA peptide review July 2026 →
Are peptides safe? →
Peptides for women over 50 →
Frequently asked questions
Is a compounded peptide the same as a "research peptide"?
No, and this is the most important distinction on this page. Compounded peptides are prepared by state-licensed 503A pharmacies (or FDA-registered 503B outsourcing facilities) under a physician's prescription for a specific patient, using APIs that come from FDA-registered suppliers. Research peptides sold "for research use only, not for human consumption" are not legal for human use in the U.S., come from unregistered suppliers, are not prepared under USP compounding standards, and are not accompanied by a certificate of analysis in most cases.
Who regulates compounding pharmacies?
State boards of pharmacy carry primary regulatory authority for 503A pharmacies, with FDA oversight over specific areas including active pharmaceutical ingredient sourcing, the do-not-compound list, and adverse-event reporting. 503B outsourcing facilities are FDA-registered directly and inspected by the FDA under cGMP (current Good Manufacturing Practice) requirements. The two tiers exist for different clinical use cases: 503A for patient-specific prescriptions, 503B for larger-batch office-use preparations.
Is compounded semaglutide safe?
Compounded semaglutide can be appropriate when sourced from a reputable 503A or 503B pharmacy under physician supervision. Quality varies significantly across the compounding market. Since brand semaglutide (Ozempic, Wegovy) returned to full commercial availability in late 2024, the FDA has narrowed the legal window for semaglutide compounding — it is now only permissible in specific patient-level circumstances documented by the prescribing physician. Compounding semaglutide as a routine cost-savings measure is no longer within FDA guidance.
Are compounded medications tested?
The pharmacy performs identity, potency, and sterility testing at the batch level, not at the finished-drug level as a manufacturer would under an FDA approval. Certificates of analysis (COAs) for the active pharmaceutical ingredient should be available on request from any reputable compounding pharmacy. If a pharmacy will not produce a COA for the API lot used in your prescription, that is a meaningful quality signal.
Are compounded peptides covered by insurance?
Almost never. Compounded medications generally sit outside standard formulary coverage. Some HSA and FSA accounts will reimburse for compounded prescriptions when accompanied by a physician's letter of medical necessity, but pharmacy benefit managers typically decline coverage.
Can any physician prescribe a compounded peptide?
Any physician licensed in the state where the patient resides can write a prescription for a compoundable substance. The right question is not "can they?" but "should they?" — clinicians without menopause, peptide, or endocrinology training may prescribe based on marketing rather than evidence. kindr routes peptide evaluations through physicians who work in these categories daily.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-06-22. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.